Circio Holding ASA (FRA:TA50)
€ 0.0006 0 (0%) Market Cap: 3.16 Mil Enterprise Value: 5.87 Mil PE Ratio: 0.98 PB Ratio: 0 GF Score: 1/100

Q3 2019 Targovax ASA Earnings Call Transcript

Nov 07, 2019 / 09:00AM GMT
Release Date Price: €10.8 (+2.06%)
TorbjÃ;rn Furuseth
Targovax ASA - CFO

¸ -

Good morning, everyone, and welcome to the third quarter presentation of Targovax. I am Torbjørn Furuseth, the CFO of the company. And together with me today also have Ãystein Soug, our CEO.

There will be forward-looking statements today. The agenda. First, we will start with a short introduction of the company and the financials and the highlights of the quarter. And then Ãystein will take you through melanoma. We will present preclinical data on our next-generation viruses, short touch-up on the mesothelioma trial and then the upcoming news flow.

Cancer therapy has gone through a paradigm shift with the introduction of immunotherapy, and this shift has been led by the checkpoint inhibitors that have cured thousands of patients and is now a $20 billion market.

Despite this success, it's actually only 10% to 40% of the patients that are responding to their checkpoint inhibitors. And for some indications, the response rates are even lower. You could be -- you could combine some other checkpoint inhibitors, but that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot